Infinium Pharmachem Ltd Stock Price Today (NSE: INFINIUM)
Fundamental Score
Infinium Pharmachem Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Infinium Pharmachem Ltd share price today is ₹219.50, up +3.54% on NSE/BSE as of 7 August 2026. Infinium Pharmachem Ltd (INFINIUM) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹331.14 (Cr). The 52-week high for INFINIUM share price is ₹276.00 and the 52-week low is ₹198.00. At a P/E ratio of 27.25x, INFINIUM is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 10.54% and a debt-to-equity ratio of 0.00.
Infinium Pharmachem Ltd Share Price Chart — NSE/BSE Historical Performance
Infinium Pharmachem Ltd share price chart: 1.78% return over the past month. 52-week high ₹276.00, 52-week low ₹198.00.
Infinium Pharmachem Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹212.00 | ₹220.00 | ₹212.00 | ₹219.50 | 7.00K (Cr) | |
| ₹208.50 | ₹210.00 | ₹208.50 | ₹209.95 | 3.50K (Cr) | |
| ₹211.75 | ₹212.00 | ₹206.50 | ₹206.95 | 2.00K (Cr) | |
| ₹208.00 | ₹209.00 | ₹202.00 | ₹202.00 | 6.00K (Cr) | |
| ₹208.50 | ₹208.50 | ₹208.50 | ₹208.50 | 500.00 (Cr) | |
| ₹209.70 | ₹209.70 | ₹206.00 | ₹206.00 | 1.50K (Cr) | |
| ₹211.50 | ₹211.50 | ₹204.50 | ₹206.05 | 2.50K (Cr) | |
| ₹208.50 | ₹209.00 | ₹205.00 | ₹209.00 | 1.50K (Cr) | |
| ₹209.50 | ₹209.50 | ₹209.50 | ₹209.50 | 500.00 (Cr) | |
| ₹216.50 | ₹216.50 | ₹205.00 | ₹210.70 | 4.00K (Cr) |
Infinium Pharmachem Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹208.00 | ₹220.00 | ₹202.00 | ₹219.50 | +5.53% | |
| ₹209.00 | ₹216.50 | ₹200.90 | ₹208.50 | -0.24% | |
| ₹218.50 | ₹218.50 | ₹208.00 | ₹210.00 | -3.89% | |
| ₹216.50 | ₹219.00 | ₹208.00 | ₹213.00 | -1.62% | |
| ₹206.50 | ₹215.95 | ₹206.00 | ₹212.00 | +2.66% | |
| ₹205.50 | ₹209.50 | ₹198.00 | ₹199.35 | -2.99% | |
| ₹219.90 | ₹228.50 | ₹210.00 | ₹224.75 | +2.21% | |
| ₹223.75 | ₹228.00 | ₹210.00 | ₹218.00 | -2.57% | |
| ₹237.20 | ₹242.00 | ₹215.00 | ₹217.15 | -8.45% | |
| ₹262.50 | ₹269.95 | ₹236.05 | ₹236.25 | -10.00% | |
| ₹253.50 | ₹259.05 | ₹240.00 | ₹249.60 | -1.54% | |
| ₹262.50 | ₹269.50 | ₹242.00 | ₹249.00 | -5.14% |
AI Research Briefing
Powered by Gemini · 2026-04-08
Infinium is a microcap pharma play trading at nosebleed valuations with negative free cash flow and promoter selling.
WHAT'S HAPPENING NOW
No major catalysts found after live search. Recent news is limited to general pharma sector updates and stock forecasts.
CORE STORY
Commoditized API manufacturer a premium multiple. Not a growth story, but a 'hope' story.
- Pharma sector hype
- Relatively high historical sales growth
- Microcap euphoria
- Unexpected order wins
- Surprise earnings beat
- Positive regulatory changes
- Rich valuation
- Promoter selling
- Negative free cash flow
- Microcap liquidity risk
Promoter decreasing stake (-5.33%).
General tailwinds for the Indian pharma sector.
Poor. Negative free cash flow of ₹-25.96 Cr over 5 years.
Expect valuation correction in the next 3-6 months as growth slows and market sentiment normalizes. Downside risk is significant.
Primary Thesis Risk
Unsustainable valuation given poor cash flow and promoter selling will lead to correction.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Infinium Pharmachem Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Infinium Pharmachem Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of INFINIUM across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Attractive Valuation (P/E: 27.25 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (75.13%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (45.17%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (21.87% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (34.90% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (7.37x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (64.91%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Weak Earnings Growth (-10.53% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-22.09 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.21%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Infinium Pharmachem Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Infinium Pharmachem Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
63.1/100 | ₹219.50₹220 | ₹331.14₹331.14 | 27.25Average 27.3 Average | 10.54%Average 10.54% Average | 13.10%Average 13.10% Average | 0.00Excellent 0.0 Excellent | 34.90%Excellent 34.90% Excellent | 21.87%Excellent 21.87% Excellent | 0.00% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Infinium Pharmachem Ltd PE Ratio History
Historical price-to-earnings ratio for INFINIUM — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹10.61 | ₹299.90 | 28.3x |
| FY 2023 | ₹6.82 | ₹235.00 | 34.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Infinium Pharmachem Ltd Quarterly Performance
Latest quarterly metrics for INFINIUM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
45.17%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
75.13%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
21.87%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
34.90%
Compounded annual net profit growth over 5 years
Infinium Pharmachem Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for INFINIUM — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Infinium Pharmachem Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Infinium Pharmachem Ltd (INFINIUM) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Infinium Pharmachem Ltd
About INFINIUM (Infinium Pharmachem Ltd)
Infinium Pharmachem Ltd (INFINIUM) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with ...a current market capitalisation of ₹331.14 (Cr). Infinium Pharmachem Ltd has delivered a Return on Equity (ROE) of 10.54% and a ROCE of 13.10%. The debt-to-equity ratio stands at 0.00, reflecting the company's capital structure. Investors tracking INFINIUM share price can monitor key metrics including P/E ratio, promoter holding of 64.91%, and quarterly earnings growth.
Company Details
INFINIUM Share Price: Frequently Asked Questions
What is the current share price of Infinium Pharmachem Ltd?
Infinium Pharmachem Ltd (INFINIUM) trades at ₹219.50 on NSE. Market cap ₹331.14 (Cr). Educational data only.
What is the P/E ratio of Infinium Pharmachem Ltd?
Infinium Pharmachem Ltd has a P/E of 27.25x vs industry average 34.89x.
What is the Bull Run score for Infinium Pharmachem Ltd?
Infinium Pharmachem Ltd has a Bull Run score of 63.1/100 based on 25+ financial parameters.
Does Infinium Pharmachem Ltd pay dividends?
Infinium Pharmachem Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Infinium Pharmachem Ltd?
Infinium Pharmachem Ltd has ROE of 10.54%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Infinium Pharmachem Ltd?
Infinium Pharmachem Ltd has debt-to-equity of 0.00.
Is Infinium Pharmachem Ltd a good investment?
Bull Run gives Infinium Pharmachem Ltd a score of 63.1/100. This is not investment advice — consult a SEBI-registered advisor.